MetLife Investment Management’s Fulcrum Therapeutics FULC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $224K | Buy |
32,545
+15,010
| +86% | +$103K | ﹤0.01% | 2130 |
|
|
2025
Q1 | $50.5K | Sell |
17,535
-22,572
| -56% | -$65K | ﹤0.01% | 2690 |
|
|
2024
Q4 | $189K | Buy |
40,107
+23,792
| +146% | +$112K | ﹤0.01% | 2332 |
|
|
2024
Q3 | $58.2K | Buy |
16,315
+417
| +3% | +$1.49K | ﹤0.01% | 2741 |
|
|
2024
Q2 | $98.6K | Buy |
+15,898
| New | +$98.6K | ﹤0.01% | 2611 |
|
|
2023
Q2 | – | Sell |
-27,689
| Closed | -$78.9K | – | 2959 |
|
|
2023
Q1 | $78.9K | Buy |
27,689
+8,799
| +47% | +$25.1K | ﹤0.01% | 2645 |
|
|
2022
Q4 | $138K | Hold |
18,890
| – | – | ﹤0.01% | 2458 |
|
|
2022
Q3 | $153K | Buy |
+18,890
| New | +$153K | ﹤0.01% | 2453 |
|
|
2022
Q2 | – | Sell |
-15,001
| Closed | -$355K | – | 2876 |
|
|
2022
Q1 | $355K | Buy |
15,001
+5,446
| +57% | +$129K | ﹤0.01% | 1992 |
|
|
2021
Q4 | $169K | Hold |
9,555
| – | – | ﹤0.01% | 2160 |
|
|
2021
Q3 | $270K | Buy |
+9,555
| New | +$270K | ﹤0.01% | 1888 |
|
|
2020
Q3 | – | Sell |
-6,267
| Closed | -$115K | – | 2315 |
|
|
2020
Q2 | $115K | Buy |
+6,267
| New | +$115K | ﹤0.01% | 2190 |
|